Early phenotype-desirable antimicrobial therapy improved 30-day clinical outcomes in Enterobacterales bloodstream infections, highlighting its benefits for antimicrobial stewardship and patient care.

Relebactam has been designed to inhibit a key resistance mechanism that limits the effectiveness of beta lactam antibiotics, including carbapenems like imipenem that have become last-line ...